Filing Details

Accession Number:
0000904454-20-000586
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-08-20 18:14:47
Reporting Period:
2020-08-18
Accepted Time:
2020-08-20 18:14:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1000694 Novavax Inc NVAX Biological Products, (No Disgnostic Substances) (2836) 222816046
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1342823 M Gregory Glenn C/O Novavax, Inc.
21 Firstfield Road
Gaithersburg MD 20878
President, R&D No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-08-18 3,200 $50.00 5,039 No 4 M Direct
Common Stock Acquisiton 2020-08-18 7,500 $25.60 12,539 No 4 M Direct
Common Stock Acquisiton 2020-08-18 4,405 $36.60 16,944 No 4 M Direct
Common Stock Acquisiton 2020-08-18 8,200 $27.00 25,144 No 4 M Direct
Common Stock Acquisiton 2020-08-18 2,733 $27.00 27,877 No 4 M Direct
Common Stock Acquisiton 2020-08-18 16,658 $27.60 44,535 No 4 M Direct
Common Stock Acquisiton 2020-08-18 13,225 $46.00 57,760 No 4 M Direct
Common Stock Disposition 2020-08-18 6,288 $143.94 51,472 No 4 S Direct
Common Stock Disposition 2020-08-18 31,957 $145.00 19,515 No 4 S Direct
Common Stock Disposition 2020-08-18 17,151 $146.00 2,364 No 4 S Direct
Common Stock Disposition 2020-08-18 525 $146.58 1,839 No 4 S Direct
Common Stock Disposition 2020-08-18 1,528 $0.00 311 No 5 G Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 5 G Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-08-18 3,200 $0.00 3,200 $50.00
Common Stock Stock Option (Right to Buy) Disposition 2020-08-18 7,500 $0.00 7,500 $25.60
Common Stock Stock Option (Right to Buy) Disposition 2020-08-18 4,405 $0.00 4,405 $36.60
Common Stock Stock Option (Right to Buy) Disposition 2020-08-18 8,200 $0.00 8,200 $27.00
Common Stock Stock Option (Right to Buy) Disposition 2020-08-18 2,733 $0.00 2,733 $27.00
Common Stock Stock Option (Right to Buy) Disposition 2020-08-18 16,658 $0.00 16,658 $27.60
Common Stock Stock Option (Right to Buy) Disposition 2020-08-18 13,225 $0.00 13,225 $46.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2021-03-10 No 4 M Direct
0 2022-03-01 No 4 M Direct
0 2023-03-02 No 4 M Direct
550 2026-11-14 No 4 M Direct
6,017 2026-11-14 No 4 M Direct
8,341 2027-12-15 No 4 M Direct
18,524 2028-12-13 No 4 M Direct
Footnotes
  1. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.45 to $144.43, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  2. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.45 to $145.44, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  3. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.47 to $146.44, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  4. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.47 to $146.67, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  5. The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 10, 2011 grant date.
  6. The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 1, 2012 grant date.
  7. The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 2, 2013 grant date.
  8. Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, subject to continued employment through such vesting date.
  9. Vesting of the shares subject to this option grant is subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which twenty-five percent (25%) of the shares vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments on the first of each month over the following three (3) years, subject to continued employment through such vesting date, and (2) a performance-based vesting requirement, pursuant to which 33.33%, 33.33%, and 33.34% of the shares vested or will vest if, at any time during the four-year period from the November 14, 2016 grant date, the volume-weighted average stock price of the Company's common stock meets or exceeds $80.00, $120.00, or $160.00, respectively, for twenty (20) consecutive trading days.
  10. Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, subject to continued employment through such vesting date.
  11. Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.